AbbVie Inc. (NYSE:ABBV) Receives $241.85 Consensus Price Target from Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have received an average recommendation of “Moderate Buy” from the twenty-five research firms that are presently covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $241.85.

A number of research analysts have recently commented on ABBV shares. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Evercore ISI increased their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. UBS Group raised their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock.

Institutional Trading of AbbVie

Institutional investors have recently modified their holdings of the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. TD Capital Management LLC raised its position in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the second quarter worth about $25,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the third quarter valued at approximately $31,000. Finally, Evolution Wealth Management Inc. acquired a new stake in AbbVie during the second quarter valued at approximately $26,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 1.1%

AbbVie stock opened at $226.24 on Wednesday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a fifty day moving average price of $228.30 and a two-hundred day moving average price of $208.54. The firm has a market cap of $399.85 billion, a price-to-earnings ratio of 171.39, a P/E/G ratio of 1.22 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the company posted $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.